Why Intercept Pharmaceuticals, Sangamo Biosciences, and eHealth Are Today's 3 Best Stocks

The S&P ekes out a small gain on positive jobs data as Intercept Pharmaceuticals nearly quadruples, and Sangamo Biosciences and eHealth rise by double-digits.

Jan 9, 2014 at 5:15PM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

The sixth trading day of the new year brought more positive economic data to the table for the broad-based S&P 500 (SNPINDEX:^GSPC); yet, it had a difficult time deciding which way it wanted to head today.

On the bright side, initial weekly jobless claims fell by 15,000 to a seasonally adjusted 330,000 from the previous week, signaling that the jobs market is slowly improving and that the unemployment rate could continue to head lower. This data shouldn't come as too much of a surprise following yesterday's ADP Employment Report, which showed that 238,000 private sector jobs were added in December -- 35,000 ahead of estimates.

However, overhang from recently weak Chinese manufacturing data, coupled with language from the Federal Reserve that it will remain cautious with the tapering of its economic stimulus known as QE3, has investors concerned that U.S. economic growth may not be on as sound a footing as the recent data would suggest.

When the closing bell rang, the S&P 500 had managed to eke out a gain of 0.64 points (0.03%) to close at 1,838.13, just its second positive close in 2014.

Leading all stocks to the upside today -- and perhaps turning in the most impressive single-day gain witnessed in years from a non-small-cap stock -- was biopharmaceutical company Intercept Pharmaceuticals (NASDAQ:ICPT), which advanced 281.1% (seriously... 281.1%!) after announcing that its mid-stage Flint trial involving obeticholic acid (OCA) for nonalcoholic steathohepatitis (NASH) was ended early due to statistically significant efficacy. NASH is a relatively common liver disease affecting up to 12% of the U.S. population and can lead to liver cirrhosis or death. Although there's a broad-market audience for OCA, and the data clearly points to strong efficacy, the execution and clinical data on OCA from here on out had best be perfect. Otherwise, the share price could easily fall.

Sticking within the health-care sector, Sangamo Biosciences (NASDAQ:SGMO), a developer of zinc finger DNA binding proteins, gained an impressive 38.3% after announcing a collaboration with Biogen Idec (NASDAQ:BIIB) to develop therapeutics to treat sickle cell disease and beta-thalassemia. The deal will net Sangamo $20 million in upfront cash, and requires Biogen Idec to pay for any external and internal research related to its collaborative studies. Furthermore, Sangamo can earn up to an additional $300 million in milestone and development payments based on its partnership. The deal makes a lot of sense for both companies when all is said and done, with Biogen gaining access to a proprietary gene modification platform, and Sangamo getting extra working capital. Ultimately, though, I'd rather not chase Sangamo any higher until it proves its worth through clinical results.

Finally, online private health insurance platform for individuals, families, and small businesses, eHealth (NASDAQ:EHTH), exploded higher by 20.7% after reporting better-than-expected preliminary revenue figures for the fourth quarter. eHealth announced that it expects to report $53 million to $55 million in revenue for the fourth quarter (consensus estimates called for $49.2 million), as product demand jumped approximately 50%. On the downside, higher marketing expenses are going to drag its quarterly results into a range of a $0.03 per-share loss to a $0.04 per-share profit. Although marketing costs are up, the simple fact that multiple technical issues have existed with Obamacare's federally run website, Healthcare.gov, gives the company ample momentum heading into the March 31 coverage cutoff deadline for health insurance in 2014. In other words, this is a rally I suspect could still have legs.

The health-care sector offers a bevy of opportunities as you can see -- but this stock's growth potential may eclipse them all!
Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free, and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers